Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (ADPT) announced that its clonoSEQ test will be featured in approximately 100 abstracts at the American Society of Hematology annual meeting.
The Dec. 12–15, 2026, meeting in New Orleans will include 27 oral presentations featuring the test. Among 20 biopharma-sponsored studies featuring clonoSEQ, four use measurable residual disease (MRD), the cancer cells remaining after treatment, as a primary endpoint and 11 as a secondary endpoint. Research highlights include using MRD to assess treatment response and inform treatment in multiple myeloma and chronic lymphocytic leukemia, and using it alongside imaging after initial treatment in diffuse large B-cell lymphoma.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.Approximately 100 ASH abstracts will feature clonoSEQ, including 27 oral presentations.
- Minor point. Forward-looking: it has not happened yet and may not happen.20 biopharma-sponsored studies feature clonoSEQ; four use MRD as a primary endpoint and 11 as a secondary endpoint.
- Minor pointMultiple myeloma studies used clonoSEQ to assess response and inform decisions about scaling back maintenance or giving additional treatment.
- Minor pointMount Sinai research using clonoSEQ identified myeloma patients with sustained MRD negativity and survival comparable to the general population.
- Minor pointChronic lymphocytic leukemia studies, including Phase 3 MAJIC, used clonoSEQ to guide treatment duration and assess response.
- Minor pointDiffuse large B-cell lymphoma data showed that clonoSEQ testing provided prognostic information after initial treatment and could complement imaging.
Negative
- None.
Key Figures
- Abstracts featuring clonoSEQ
- approximately 100 abstracts
- ASH 2026
- Oral presentations
- 27
- Among abstracts featuring clonoSEQ at ASH 2026
- Biopharma-sponsored studies
- 20
- Unique studies featuring clonoSEQ
- Primary MRD endpoint
- 4 studies
- Among 20 unique biopharma-sponsored studies
- Secondary MRD endpoint
- 11 studies
- Among 20 unique biopharma-sponsored studies
Key Terms
measurable residual disease medical
next-generation sequencing technical
in vitro diagnostic medical
laboratory-developed test regulatory
pet/ct medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies
SEATTLE, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in approximately 100 abstracts, including 27 oral presentations, at the 68th Annual Meeting of the American Society of Hematology (ASH), taking place Dec. 12–15, 2026, in New Orleans.
The research at this year’s meeting reflects the continued evolution of MRD assessment across hematologic malignancies, moving beyond measuring the depth of treatment response to informing how therapies are developed, evaluated, and adapted based on individual patient response. Across 20 unique biopharma-sponsored studies featuring clonoSEQ, MRD is utilized as a primary endpoint in four studies and a secondary endpoint in 11, underscoring how highly sensitive MRD assessment has become integral to evaluating therapeutic efficacy and advancing new treatment approaches.
Key highlights include:
- Advancing MRD-informed treatment strategies in multiple myeloma: At ASH, data from pivotal Phase 3 studies, including PERSEUS, AURIGA, and BENEFIT, reinforce clonoSEQ's established role in evaluating treatment response, while research from PERSEUS and IMMUNOPLANT highlights its use in informing treatment strategies, including maintenance de-escalation and consolidation therapy. Additionally, real-world research from the Icahn School of Medicine at Mount Sinai leveraging clonoSEQ data identifies patients with sustained MRD negativity and survival comparable to the general population, highlighting the ability to inform treatment discontinuation and providing new evidence supporting the possibility of cure in multiple myeloma.
- Evaluating MRD-guided treatment in chronic lymphocytic leukemia (CLL): Several studies, including the Phase 3 MAJIC study, demonstrate the use of clonoSEQ in guiding the duration of therapy and assessing response. In addition, in the MIRACLE study, MRD is also used as a primary endpoint.
- Strengthening MRD testing utility relative to PET/CT in lymphoma: New real-world data from Adaptive, Hackensack University Medical Center, and the University of Nebraska Medical Center, as well as study data from Wilmot Cancer Center, show the prognostic value of clonoSEQ MRD assessment following frontline treatment in diffuse large B-cell lymphoma (DLBCL), including its ability to complement imaging.
"The research being presented at ASH underscores clonoSEQ's established position in pivotal clinical trials and showcases its ever-expanding role as a tool to inform patient care strategies across blood cancers,” said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. “Multiple myeloma offers a powerful example of this progress, with updated clinical guidelines, a new definition of cure, and important Phase 3 research reinforcing the value of systematic MRD assessment. With a strong foundation of clinical evidence, regulatory validation and unparalleled real-world patient experience, Adaptive is helping shape the future of MRD-guided care for blood cancer patients.”
A list of selected abstracts featuring clonoSEQ is available here.
About clonoSEQ®
clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), T-cell acute lymphoblastic leukemia (T-ALL), and other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ASH 2026 abstracts and oral presentations will feature Adaptive Biotechnologies’ clonoSEQ test?
clonoSEQ will be featured in approximately 100 abstracts, including 27 oral presentations, at the American Society of Hematology annual meeting.
What did the Mount Sinai study highlighted by Adaptive Biotechnologies at ASH 2026 find in multiple myeloma?
The Mount Sinai study identified patients with sustained MRD negativity and survival comparable to the general population. The researchers used real-world clonoSEQ data to identify patients whose tests continued to show no detectable residual disease.